In the primary result from the largest double-blind study ever completed to assess a drug's effect in the prevention of stroke in patients with atrial fibrillation, a common heart rhythm abnormality, rivaroxaban, an anti-clotting drug, was shown to be an attractive alternative to warfarin, the...
Pradaxa (dabigatran etexilate), an anticoagulant, has been approved in capsule form for the prevention of blood clots and strokes in individuals with atrial fibrillation by the US Food and Drug Administration (FDA). People with atrial fibrillation - abnormal heart rhythm - are more susceptible...